Delivery Order SPE2DB20D9127-SPE2DB25FPRM5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count units). This firm fixed-price delivery order, issued on August 8, 2025, with an ultimate completion date of August 11, 2025, represents a discrete procurement action under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The award...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count units) with a ceiling value of $8,339.18. This firm fixed-price delivery order, issued on September 11, 2025, with ultimate completion by September 12, 2025, represents a routine pharmaceutical supply transaction under DMS Pharmaceutical Group's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The delivery order, issued on July 16, 2025, with an ultimate completion date of July 17, 2025, carries firm fixed-price terms and represents a direct procurement with no set-aside designation. This award falls under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count packaging). This firm fixed-price delivery order, valued at $4,169.59, was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025. The contract carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation. The award is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, was issued without a set-aside designation. The award represents a single delivery order issued under DMS...
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 11, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units) under a firm fixed-price contract valued at $8,622.72. The contract, awarded on September 16, 2025, with an ultimate completion date of September 17, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules in quantities of 120 units. This $17,245.40 firm fixed-price delivery order was awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, and carries no set-aside designation. The order falls under DMS Pharmaceutical Group's existing single-award Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB25FPRM5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count). The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025, under a firm fixed-price contract type with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $500 million indefinite delivery vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products for military health facilities. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its woman-owned small business status to compete effectively in DLA procurement markets. The company specializes in distributing branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to Department of Defense healthcare facilities nationwide. Xtandi, an oncology treatment, represents one of the specialized pharmaceutical products the vendor regularly supplies through its IDC arrangement, demonstrating the company's capability to provide high-value pharmaceutical items supporting military medical operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 9/17/25 |